Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this conversion therapy study is to evaluate the safety and efficacy of
neoadjuvant of Tislelizumab combined with platinum doublet for stage III unresectable locally
advanced NSCLC.